Piper Jaffray analyst Edward Tenthoff raised his price target on Regeneron Pharma (NASDAQ: REGN) to $484.00 (from $415.00) following results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Canaccord Genuity Raises PT of Regeneron Pharmaceuticals (REGN) to $525 from $460May 8, 2015 10:35 AM Regeneron (REGN) PT Lifted to $507 at Brean Capital Amid Strong Eylea SalesMay 8, 2015 8:26 AM Regeneron Pharma (REGN) PT Lifted to $490 at Roth CapitalMay 7, 2015 1:21 PM Regeneron (REGN) Tops Q1 EPS by 20c; Boosts U.S. EYLEA Sales OutlookMay 7, 2015 6:34 AM Regeneron Reports First Quarter 2015 Financial and Operating ResultsMay 7, 2015 6:30 AM